Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) saw a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 8,600 shares, a decline of 86.8% from the January 15th total of 65,100 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Antibe Therapeutics Stock Performance

OTCMKTS:ATBPF remained flat at $0.22 on Wednesday. Antibe Therapeutics has a 12-month low of $0.11 and a 12-month high of $0.89. The company has a market cap of $11.42 million, a P/E ratio of -0.86 and a beta of 0.51. The company has a fifty day moving average of $0.22 and a 200-day moving average of $0.22.

About Antibe Therapeutics

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).